Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD

Part of paid clinical trials in Charlotte, North Carolina.

Sponsor
Aqtual, Inc.
Study ID
NCT05936970
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies.

Key Dates

Start date
Jun 29, 2023
Status verified
Nov 2024
Primary completion
Jun 30, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
1,410 participants (estimated)

Arms

  • Arm: Adults diagnosed with RA
    Adults diagnosed with RA who are planning to initiate a new bDMARD +/- csDMARD or tsDMARD +/- csDMARD treatment

Primary Outcome Measure

Clinical Response Prediction [ Time Frame: Approximately 3 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Arthritis and Osteoporosis Consultants of the CarolinasCharlotteNorth Carolina28207
Coordinator

Find similar trials in Charlotte, NC

By condition
Rheumatoid arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
Arthritis and Osteoporosis Consultants of the Carolinas· Charlotte, NC

Related Studies